Tananbaum James B.'s Form 4 filing
Latigo Biotherapeutics, Inc. (LTGO) · filed Aug 10, 2026
- Accession no.
- 0001581754-26-000006
- Filed
- Aug 10, 2026, 8:00 PM ET
- Trade date
- Aug 10, 2026
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not checked
This filing lists 8 non-derivative transactions and 7 derivative transactions. Open-market purchases total $2.52M. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Tananbaum James B.CIK 0001581754 | Director, 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 10, 2026 | Common Stock | CConversionAcquired | +3,117,664 | –F1 | – | 3,117,664 | Indirect | |
| Aug 10, 2026 | Common Stock | CConversionAcquired | +445,320 | –F1 | – | 3,562,984 | Indirect | |
| Aug 10, 2026 | Common Stock | CConversionAcquired | +1,125,823 | –F1 | – | 1,125,823 | Indirect | |
| Aug 10, 2026 | Common Stock | CConversionAcquired | +742,201 | –F1 | – | 1,868,024 | Indirect | |
| Aug 10, 2026 | Common Stock | PPurchaseAcquired | +140,000 | $18.00 | +$2,520,000 | 2,008,024 | Indirect | |
| Aug 10, 2026 | Common Stock | CConversionAcquired | +195,776 | –F4 | – | 2,203,800 | Indirect | |
| Aug 10, 2026 | Common Stock | CConversionAcquired | +3,117,664 | –F1 | – | 3,117,664 | Indirect | |
| Aug 10, 2026 | Common Stock | CConversionAcquired | +296,880 | –F1 | – | 3,414,544 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 10, 2026 | Common Stock | CConversionDisposed | −3,117,664 | –F1 | – | 0 | Indirect | |
| Aug 10, 2026 | Common Stock | CConversionDisposed | −445,320 | –F1 | – | 0 | Indirect | |
| Aug 10, 2026 | Common Stock | CConversionDisposed | −1,125,823 | –F1 | – | 0 | Indirect | |
| Aug 10, 2026 | Common Stock | CConversionDisposed | −742,201 | –F1 | – | 0 | Indirect | |
| Aug 10, 2026 | Common Stock | CConversionDisposed | −3,117,664 | –F1 | – | 0 | Indirect | |
| Aug 10, 2026 | Common Stock | CConversionDisposed | −296,880 | –F1 | – | 0 | Indirect | |
| Aug 10, 2026 | Common Stock | CConversionDisposed | −195,776 | –F4 | – | 0 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Each share of preferred stock converted automatically into 1 share of common stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The preferred stock had no expiration date.
Referenced by the price of 6 transactions in Table I and 6 transactions in Table II.
- F4
Reflects a convertible note that is convertible into shares of Common Stock of the Issuer. The convertible note has a maturity date of June 17, 2027. The principal amount of the convertible note together with any accrued but unpaid interest automatically converted into shares of Common Stock of the Issuer upon the closing of the Issuer's initial public offering at a conversion price equal to the initial public offering price of the Issuer's common stock.
Referenced by the price of 1 transaction in Table I and 1 transaction in Table II.